Company intelligence / Profile preview

George Medicines

Staines-Upon-Thames, England, United Kingdomgeorge-medicines.com ↗

Ownership: Private
Development stage: Phase 3

Overview

George Medicines develops late-stage, single-pill combination therapies to address significant unmet needs in cardiometabolic diseases. Their approach leverages existing best-in-class treatments combined into innovative formulations. Lead programs are in advanced clinical trials targeting hypertension and cardiovascular risk reduction. Recent licensing agreements indicate progress toward commercialization.

Therapeutic areas: CardiovascularMetabolic Disorders
Modalities: Small moleculesfixed-dose combination therapies
Industry: Biotech

Drug pipeline

1 asset

GMRx4

Unknown

Partnerships

Medisanté (IoT data collection collaboration)Bausch Health (exclusive licensing agreement for certain territories)Contractual pharmaceutical/clinical development partners

Beyond the preview

Go deeper on George Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on George Medicines.

Explore the full profile